COMMUNIQUÉS West-GlobeNewswire

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
13/05/2025
SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has [...]
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
13/05/2025
Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a [...]
Excision BioTherapeutics Presents Data from HBV and HSV Programs at the ASGCT 2025 Annual Meeting
13/05/2025
Poster presentation to demonstrate EBT-107’s potential to reduce clinically-relevant biomarkers and HBV DNA integration toward functional remission of chronic hepatitis B Oral presentation to highlight significant [...]
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
13/05/2025
Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar Market Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( [...]
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
13/05/2025
Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 2025 (GLOBE NEWSWIRE [...]
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
13/05/2025
Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Association of [...]
Doheny Eye Institute Announces Kaustabh Ghosh, Ph.D. as the Mary D. Allen Endowed Chair in Vision Research
13/05/2025
Dr. Ghosh is an interdisciplinary vision researcher with an interest in investigating the mechanisms underlying early diabetic retinopathy and age-related macular degeneration PASADENA, Calif., May 13, 2025 (GLOBE [...]
Complement 1 Secures $16M Seed Round to Scale Clinically Validated Cancer Lifestyle Modification Platform
13/05/2025
Evidence-based lifestyle modification platform for oncology achieves 90%+ adherence with new dedicated CoActive Coach model, significantly improving cancer-related health outcomes. NEW YORK, May 13, 2025 (GLOBE NEWSWIRE [...]
Visory Health Expands Veteran Support Through New Partnership with Hope for the Warriors
13/05/2025
The new partnership introduces healthcare resources for Veterans and military families, helping reduce out-of-pocket medication costs ESTERO, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Visory Health , a patient-first health [...]
Shineco’s Subsidiary InfiniClone Partners with Total World Marketing for Entry into the Southeast Asian Healthcare Market
13/05/2025
BEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that InfiniClone [...]
AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today
13/05/2025
See how innovation is transforming patient outcomes through real-world clinical insights and patient stories VALENCIA, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading [...]
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
13/05/2025
— Dr. Binks joins Capricor in anticipation of potential approval of deramiocel in Q3 2025, bringing extensive experience in neuromuscular and rare diseases — SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor [...]
General Oncology to Participate in Three Upcoming Conferences
13/05/2025
BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class treatments for metastatic cancers, today announced that members of its [...]
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
13/05/2025
– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently – SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- [...]
Serotonin Centers Announces Landmark Southeast Florida Area Development
13/05/2025
Leading National Anti-Aging Med Spa Franchise Signs Multi-Unit Agreement for 18 New Locations in the South Florida Region MIAMI and FORT LAUDERDALE, Fla. and PALM BEACH, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Serotonin [...]
BON Debuts Groundbreaking Broccoli-Derived Sleep Wellness Line, Reshaping the Sleep Health Market through Innovative Technology
13/05/2025
XI’AN, China, May 13, 2025 (GLOBE NEWSWIRE) -- BON Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), a leading provider of bio-ingredient solutions for the natural health and personal care sectors, today [...]
Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics
13/05/2025
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) , a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for [...]
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
13/05/2025
MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage regenerative medicine innovator focused on stem cell-based [...]
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market
13/05/2025
Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here Additional indications potentially double the addressable [...]

Pages